Marvell Lumentum Deal: The $3.2bn Regulatory Break Fee and the Approvals Ahead

What Marvell and Lumentum agreed

Marvell will acquire Lumentum by a two-step merger in which each Lumentum share converts into 4.500 Marvell shares, a fixed exchange ratio with no cash element. According to the joint press release, that implied about $1,132 per Lumentum share, a premium of roughly 23.9% to the unaffected closing prices of 28 October 2026, the last trading day before speculation began. Marvell stockholders will own about 67% of the combined company on a fully diluted basis and Lumentum stockholders about 33%.

The boards of both companies approved the transaction unanimously. Matt Murphy stays as chairman and chief executive, and three Lumentum directors, including chief executive Michael Hurlston, will join Marvell's seven-member board. The companies point to a combined addressable market of $550 billion and more than $1 billion of annual run-rate cost synergies.

Term	What the filings say
Signed / announced	1 November 2026 / 2 November 2026
Consideration	4.500 Marvell shares per Lumentum share, all stock
Implied value	$115bn enterprise value; about $1,132 per share
Premium	About 23.9% to unaffected prices of 28 October 2026
Ownership after closing	Marvell holders about 67%, Lumentum holders about 33%
Expected closing	First half of calendar 2028
Outside date	1 November 2027, extendable to 1 August 2028 for regulatory delay
Advisers	Marvell: Qatalyst Partners, J.P. Morgan, Goldman Sachs, Wilson Sonsini. Lumentum: Citigroup, Evercore, Davis Polk

The market's verdict on the Marvell Lumentum deal was cool. CNBC reported that Marvell shares fell 13% and Lumentum shares nearly 19% in Monday trading. Because the ratio is fixed, that fall flows straight into the value Lumentum holders will receive. TechCrunch, citing the Wall Street Journal, put the equity value at about $80 billion, against the $115 billion enterprise value that includes debt, and placed the deal above Microsoft's $68.7 billion Activision Blizzard purchase.

Which approvals the Marvell Lumentum acquisition needs

The short answer is shareholder votes on both sides, US merger control under the Hart-Scott-Rodino Act, and a list of other regulatory approvals that the public filings do not name. The Form 8-K lists the closing conditions: adoption of the agreement by Lumentum stockholders; approval by Marvell stockholders of the share issuance and a charter amendment to increase its authorised shares; expiry of the HSR waiting period "and the receipt of certain other required regulatory approvals"; no legal restraint; an effective Form S-4; Nasdaq listing of the new shares; and no material adverse effect on either company.

Under the HSR Act the initial waiting period ends 30 days after both parties file, but the Federal Trade Commission or the Justice Department can extend it by issuing a request for additional information, commonly called a second request. The merger agreement commits both parties to make their HSR filings within 15 business days of signing.

The other approvals sit in Section 7.1(c) of Marvell's disclosure letter, which is not public. What the agreement does reveal is breadth: its definition of "Regulatory Laws" covers antitrust law and any US or non-US law that regulates investment "on public order or national security grounds". That matters because Lumentum's most recent annual report says its significant manufacturing facilities are in the United States, Thailand, China, the United Kingdom, Slovenia and Japan. Each of those footprints raises its own filing analysis, and the parties have not said publicly which jurisdictions are on the list. For a recent example of a multi-agency process, see our account of how the Paramount and Warner Bros. merger cleared regulators.

In the UK, the National Security and Investment Act guidance lists 17 sensitive areas where acquirers may be legally required to notify. The Advanced Materials area expressly covers semiconductors and "photonic and optoelectronic materials and devices", and Computing Hardware is a separate area. Whether a mandatory filing is triggered depends on what a UK entity actually does, so advisers will need the facts of Lumentum's British operations before deciding. Readers who need specialist help can search our directory of US competition lawyers or export control and trade advisers.

How the merger agreement allocates regulatory risk

Marvell carries most of the regulatory risk, but not all of it. Section 6.3 of the agreement requires both sides to use "reasonable best efforts" to obtain clearance before the outside date, and then goes further. To remove "each and every impediment" under any Regulatory Law, the parties must offer what the agreement calls Remedial Actions: selling, licensing or holding separate businesses; ending or amending contracts and joint ventures; granting commercial accommodations to third parties, "including agreeing to minimum supply, pricing or other similar commitments"; and accepting behavioural limits.

There is a ceiling. Marvell is not obliged to accept any remedy that "would reasonably be expected to be material (in an adverse manner)" to the combined business taken as a whole, or one not conditioned on closing. That is the Burdensome Condition. Lumentum cannot offer remedies without Marvell's consent, but must implement those Marvell directs. Neither party may withdraw a filing or agree to extend a waiting period without the other's consent, and neither may buy a competing business if doing so would make clearance materially less likely or materially slower.

The supply-commitment language is notable. Where a merger joins makers of complementary components that other manufacturers also buy, competition authorities sometimes seek assurances of continued supply to third parties, and the agreement expressly anticipates that kind of commitment. Deal teams negotiating similar transactions can compare the approach with the remedies debate in the Paramount Skydance and Warner Bros. Discovery review and the European Commission's practice under the EU Foreign Subsidies Regulation.

The break fees in the Marvell Lumentum deal

The agreement sets three fees, and the regulatory fee is the one most likely to matter. Marvell pays $3.2 billion if the deal fails for regulatory reasons, which is roughly 2.8% of the $115 billion enterprise value, provided every non-regulatory condition is met or capable of being met at the time.

Fee	Amount	Main triggers
Marvell termination fee	$5.8bn	Marvell board changes its recommendation; Marvell takes a superior proposal; certain tail cases where Marvell agrees a deal for a majority of itself within 12 months
Lumentum termination fee	$2.9bn	Reciprocal triggers on the Lumentum side
Regulatory termination fee	$3.2bn, paid by Marvell	Outside date passes, a final non-appealable antitrust or foreign investment restraint, or a final denial of a required approval

The asymmetry is worth noticing: Marvell's fee is twice Lumentum's, and both companies' stockholders must vote. Both sides are bound by a no-shop clause with a fiduciary out for an unsolicited superior proposal, and Lumentum must tell Marvell within 24 hours of receiving any alternative proposal. The outside date of 1 November 2027 can roll to 1 February, 1 May and finally 1 August 2028 if regulatory approvals are still outstanding, which suggests the parties expect at least one lengthy review. Corporate teams can find M&A lawyers in the United States through our directory.

Nvidia's stake and the preferred stock election

Nvidia is an investor in both companies, and the agreement has a mechanism built for that. On 2 March 2026, according to Lumentum's annual report, Lumentum sold about 2.9 million shares of Series A Convertible Preferred Stock to Nvidia at $695.31 a share, for $2.0 billion. TechCrunch reports that Nvidia also invested $2 billion in Marvell later that month.

Under the merger agreement, holders of Lumentum's Series A preferred can take Marvell common stock on an as-converted basis, or elect to receive new Marvell Series B Convertible Preferred Stock designed to carry the same terms and rights. Lumentum's equity awards roll into Marvell awards using the same 4.500 ratio, with performance units converted into time-vesting units. On CNBC, Mr Murphy rejected suggestions of circular dealmaking and called the combination a "double down on supporting Nvidia". For investors watching supply chains, our report on the Wingtech and Nexperia dispute shows how quickly semiconductor ownership can become a geopolitical question.

What happens next for the Marvell Lumentum deal

The next public step is a joint registration statement on Form S-4 containing the proxy statement for both shareholder meetings. HSR filings are due within 15 business days of 1 November, so the 30-day clock is likely to start this month, and other filings follow the non-public list.

Disputes are channelled to one place. The parties submit to the exclusive jurisdiction of the Delaware Court of Chancery and agree that either may obtain specific performance without proving damages, so a reluctant party could be ordered to close rather than simply pay. With both share prices down after the announcement, the Marvell Lumentum deal now has to hold two shareholder bases together for up to 21 months. For more on the market backdrop, see our analysis of whether China's AI bubble has burst, or browse corporate and M&A advisers and advisers in China.

Frequently asked questions

What are the Marvell Lumentum deal terms?

Lumentum stockholders will receive a fixed 4.500 Marvell shares for each Lumentum share, with no cash. The companies say this implies an enterprise value of $115 billion, about $1,132 per share and a 23.9% premium. Lumentum holders will own about 33% of the combined company.

When will the Marvell Lumentum acquisition close?

The companies expect closing in the first half of calendar 2028. The agreement's outside date is 1 November 2027, but it can be extended in stages to 1 August 2028 if required regulatory approvals are still pending.

What happens if regulators block the deal?

If the merger fails because of a final antitrust or foreign investment restraint, a final denial of a required approval, or the outside date passing while only regulatory conditions remain, Marvell must pay Lumentum a $3.2 billion regulatory termination fee.

Do shareholders have to approve the deal?

Yes. Lumentum stockholders must adopt the merger agreement, and Marvell stockholders must approve the issuance of the new shares and a charter amendment increasing Marvell's authorised share capital. Both votes follow a joint proxy statement filed with the SEC.

Does Marvell have to sell businesses to win clearance?

It must offer divestments, licences, supply commitments and other remedies needed to clear the deal, unless a remedy would be materially adverse to the combined business as a whole or is not conditioned on closing. That limit is defined as a Burdensome Condition.

Why did Marvell and Lumentum shares fall?

CNBC reported falls of 13% for Marvell and nearly 19% for Lumentum on 2 November, noting that the deal comes amid concerns about how long AI infrastructure spending can last. Because the exchange ratio is fixed, the value Lumentum holders receive moves with Marvell's share price.

Sources

1. Marvell Technology, Inc., Form 8-K (Item 1.01), filed 2 November 2026: SEC EDGAR
2. Agreement and Plan of Merger dated 1 November 2026, Exhibit 2.1: SEC EDGAR
3. Joint press release, "Marvell and Lumentum to Combine", 2 November 2026, Exhibit 99.1: SEC EDGAR
4. Lumentum Holdings Inc., Annual Report on Form 10-K for the fiscal year ended 27 June 2026: SEC EDGAR
5. 15 U.S.C. section 18a (Hart-Scott-Rodino Act premerger notification): Legal Information Institute
6. Cabinet Office, National Security and Investment Act: details of the 17 types of notifiable acquisitions: GOV.UK
7. CNBC, 2 November 2026: cnbc.com
8. TechCrunch, 2 November 2026: techcrunch.com

About this article

Researched and written by The Corporate INTL Newsroom from the companies' SEC filings, the merger agreement, the statutes and official guidance cited and contemporaneous reporting. It is general information, not legal or investment advice. Last reviewed 3 November 2026. For more analysis visit our newsroom or subscribe to our newsletter.